Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | DRD2 | P14416 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217387 | 1.00 | CCR3 (1.00) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL6217391 | 1.00 | CCR3 (1.00) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL18840801 | 0.92 | CCR3 (1.00) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL7508708 | 0.92 | CCR3 (0.84) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL7508703 | 0.92 | CCR3 (0.84) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL6403335 | 0.91 | CCR3 (1.00) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL18840907 | 0.91 | CCR3 (1.00) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL29372294 | 0.91 | CCR3 (1.00) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| Hydrochloric Acid SCHEMBL6421288 | 0.90 | CCR3 (0.98) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL7550158 | 0.89 | CCR3 (0.97) | CCR3HTR2ACYP2D6DRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161240-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | claimed |
| US-20030114489-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2003-06-19 | — | — | US | claimed |
| US-6444686-B1 | FOR THE PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES. | BRSITOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-03 | — | — | US | claimed |
| EP-1161240-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6897234-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050096325-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2005-05-05 | — | — | US | disclosed |
| US-20030114489-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2003-06-19 | — | — | US | disclosed |
| US-6444686-B1 | FOR THE PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES. | BRSITOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-03 | — | — | US | disclosed |
| EP-1161240-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1161240-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035452-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096325-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CCR3 1/4885HTR2A 1476/4885CYP2D6 3450/4885 |
| US-20030114489-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885HTR2A 1608/4885CYP2D6 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.